• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[多发性硬化症的病程与预后。1:自然病程]

[Course of illness and prognosis of multiple sclerosis. 1: The natural illness course].

作者信息

Flachenecker P, Hartung H P

机构信息

Klinische Forschungsgruppe für Multiple Sklerose und Neuroimmunologie, Neurologische Klinik und Poliklinik, Julius-Maximilians-Universität, Würzburg.

出版信息

Nervenarzt. 1996 Jun;67(6):435-43.

PMID:8767197
Abstract

This review summarizes the natural history of multiple sclerosis (MS) in terms of disease type, survival, relapse rate and recovery as well as disability. The course of Ms is highly variable and individually difficult to predict. In epidemiological studies, the most common type of MS is the relapsing-remitting form. However, after 10-15 years of disease duration, 30-40% of patients will develop chronic progressive MS. Survival of all MS patients is only mildly affected, but markedly decreased in severely disabled patients mainly due to secondary complications. Suicide is more frequent in MS patients than in normals, especially within the first 5 years of the disease. The mean relapse rate ranges from approximately 0.5 to 0.8 relapses per year and decreases with time. Most patients will recover from relapses within 4 weeks. 50% of patients will require some form of walking aid within 15-18 years from onset. 20-40% of patients have ,,benign" MS, i.e. no or only mild disability after 10 years of MS.

摘要

本综述从疾病类型、生存率、复发率、恢复情况以及残疾程度等方面总结了多发性硬化症(MS)的自然史。MS的病程高度可变,个体情况难以预测。在流行病学研究中,最常见的MS类型是复发缓解型。然而,在病程10 - 15年后,30 - 40%的患者会发展为慢性进展型MS。所有MS患者的生存率仅受到轻微影响,但在严重残疾患者中显著降低,主要是由于继发并发症。MS患者自杀的频率高于正常人,尤其是在疾病的前5年内。平均复发率约为每年0.5至0.8次复发,且随时间降低。大多数患者会在4周内从复发中恢复。50%的患者在发病后15 - 18年内将需要某种形式的助行器。20 - 40%的患者患有“良性”MS,即在患MS 10年后无残疾或仅有轻微残疾。

相似文献

1
[Course of illness and prognosis of multiple sclerosis. 1: The natural illness course].[多发性硬化症的病程与预后。1:自然病程]
Nervenarzt. 1996 Jun;67(6):435-43.
2
Natural history of multiple sclerosis: a unifying concept.多发性硬化症的自然史:一个统一的概念。
Brain. 2006 Mar;129(Pt 3):606-16. doi: 10.1093/brain/awl007. Epub 2006 Jan 16.
3
[Course of illness and prognosis of multiple sclerosis. 2: Predictive value of clinical and paraclinical factors].[多发性硬化症的病程与预后。2:临床及临床旁因素的预测价值]
Nervenarzt. 1996 Jun;67(6):444-51.
4
The natural history of multiple sclerosis.多发性硬化症的自然病史。
Neurol Clin. 1995 Feb;13(1):119-46.
5
Long-term survival of patients with multiple sclerosis in West France.法国西部多发性硬化症患者的长期生存率
Mult Scler. 2007 Aug;13(7):865-74. doi: 10.1177/1352458507077410.
6
Prognostic factors of multiple sclerosis in Lebanon.黎巴嫩多发性硬化症的预后因素。
Int J Neurosci. 2010 Mar;120(3):206-10. doi: 10.3109/00207450903464587.
7
[The natural history of multiple sclerosis].[多发性硬化症的自然病史]
Rev Prat. 2006 Jun 30;56(12):1313-20.
8
Predictors of relapse rate in MS clinical trials.多发性硬化症临床试验中复发率的预测因素。
Neurology. 2005 Dec 13;65(11):1769-73. doi: 10.1212/01.wnl.0000187122.71735.1f.
9
Diagnosing and managing multiple sclerosis.多发性硬化症的诊断与管理
Practitioner. 2009 Sep;253(1721):25-30, 2-3.
10
Post-marketing survey on clinical response to interferon beta in relapsing multiple sclerosis: the Roman experience.复发型多发性硬化症中干扰素β临床反应的上市后调查:罗马经验
Neurol Sci. 2005 Dec;26 Suppl 4:S174-8. doi: 10.1007/s10072-005-0510-x.

引用本文的文献

1
Myelin damage and repair in pathologic CNS: challenges and prospects.病理性中枢神经系统中的髓鞘损伤与修复:挑战与前景
Front Mol Neurosci. 2015 Jul 27;8:35. doi: 10.3389/fnmol.2015.00035. eCollection 2015.
2
Glatiramer acetate in treatment of multiple sclerosis: a toolbox of random co-polymers for targeting inflammatory mechanisms of both the innate and adaptive immune system?醋酸格拉替雷治疗多发性硬化症:一种用于靶向先天性和适应性免疫系统炎症机制的随机共聚物工具箱?
Int J Mol Sci. 2012 Nov 9;13(11):14579-605. doi: 10.3390/ijms131114579.